The 1mg dose of semaglutide is where many patients start to see real momentum in their weight loss journey. If you are at this dose or approaching it, you are likely wondering what kind of results are typical. How much weight do people actually lose? How does 1mg compare to lower and higher doses?

This guide examines the clinical trial data, explains how the 1mg dose fits into the broader weight loss picture, and discusses the many factors that influence individual outcomes. Your physician can help you set realistic expectations based on your specific health profile.

Where 1mg Sits in the Dosing Hierarchy

In the STEP clinical trials for weight management, 1mg was the third step in a five-step escalation:

• Weeks 1 through 4: 0.25mg once weekly
• Weeks 5 through 8: 0.5mg once weekly
• Weeks 9 through 12: 1.0mg once weekly
• Weeks 13 through 16: 1.7mg once weekly
• Week 17 onward: 2.4mg once weekly (maintenance)

Importantly, 1mg is also the approved maintenance dose for Ozempic (semaglutide for type 2 diabetes). The SUSTAIN clinical trials studied 1mg as a standalone therapeutic dose and demonstrated meaningful weight loss in addition to blood sugar improvements.

This gives us more data on what 1mg can do as a dose level, even though it functions as a titration step in the weight management protocol.

What the Clinical Trials Showed

STEP Trials (Weight Management)

The STEP 1 trial reported average weight loss of approximately 14.9% of body weight over 68 weeks at the 2.4mg maintenance dose, compared to approximately 2.4% with placebo.

The trial did not report separate weight loss figures for each titration dose. However, based on the progressive weight loss curves published in the trial data, we can observe that meaningful weight reduction was already underway during the 1mg phase (weeks 9 through 12), with acceleration continuing at higher doses.

SUSTAIN Trials (Type 2 Diabetes)

The SUSTAIN trials provide more specific data on the 1mg dose because it was studied as a maintenance dose in the diabetes population. In the SUSTAIN 1 trial, participants on semaglutide 1mg lost an average of approximately 3.7 kg (about 8.2 lbs) over 30 weeks, compared to 1.0 kg with placebo.

It is important to note that the SUSTAIN trials enrolled patients with type 2 diabetes, not a general weight management population. Weight loss tends to be lower in diabetes populations compared to those without diabetes. The results from SUSTAIN are not directly comparable to the STEP program but provide valuable context for the 1mg dose level.

Cumulative Weight Loss Through Week 12

Based on the STEP trial weight loss curves, patients on the semaglutide treatment arm had typically lost approximately 4 to 6 percent of their body weight by week 12 (the end of the 1mg phase). This is a cumulative figure that includes the contributions from the 0.25mg and 0.5mg phases. Individual results varied widely around this average.

How Semaglutide Produces Weight Loss at 1mg

At the 1mg dose, the medication's primary mechanisms of action are well-established in the body:

• Central appetite regulation: Semaglutide acts on GLP-1 receptors in the brain to reduce hunger signals and increase feelings of fullness. At 1mg, this effect is noticeably stronger than at lower doses.
• Delayed gastric emptying: Food stays in the stomach longer, leading to earlier and more prolonged satiety after meals.
• Reduced caloric intake: The combined appetite and satiety effects lead to a natural reduction in daily caloric intake, which drives weight loss.
• Metabolic effects: Improvements in insulin sensitivity and glucose metabolism support favorable changes in body composition.

At 1mg, these effects are strong enough to produce consistent, measurable weight loss in most patients, though the magnitude varies considerably from person to person.

Why Your Results May Differ From the Average

Trial averages represent the midpoint of a wide distribution. In every clinical trial, some participants lost significantly more than average, while others lost less. The factors that influence your position on that spectrum include:

• Starting weight and BMI: Patients with higher baseline weights may lose more absolute weight but a similar percentage of body weight.
• Dietary adherence: The STEP trials combined semaglutide with a reduced-calorie diet and lifestyle counseling. Patients who made meaningful dietary changes saw better results.
• Physical activity: Regular exercise supports greater weight loss and helps preserve lean muscle mass.
• Metabolic health: Insulin resistance, thyroid function, hormonal status, and other metabolic factors affect the pace of weight loss.
• Genetics: Individual genetic variation influences GLP-1 receptor sensitivity and metabolic response to the medication.
• Age and sex: These factors can influence metabolism, body composition, and medication response.
• Sleep and stress: Poor sleep and chronic stress disrupt hormones that regulate appetite and metabolism.
• Medication adherence: Consistent, on-schedule dosing is important for maintaining steady drug levels and optimal therapeutic effect.

What Affects Your Weight Loss at 1mg Specifically

• How long you stay at this dose: Patients who spend longer at 1mg (beyond the standard four weeks) may see more cumulative weight loss at this dose level, though the weekly rate may be lower than what is achievable at higher doses.
• Your response to lower doses: If you were already seeing weight loss at 0.25mg and 0.5mg, 1mg is likely to build on that momentum.
• Whether 1mg is your maintenance dose: If your physician determines that 1mg is your long-term dose (rather than a titration step), your total weight loss will reflect steady use at this level over months.
• Caloric deficit: Even with reduced appetite, the size of your caloric deficit determines the pace of weight loss. Working with a nutritionist can help you optimize intake.
• Muscle-preserving strategies: Adequate protein intake and resistance training help ensure that weight loss comes primarily from fat rather than muscle.

Comparing 1mg to Other Doses

The dose-response relationship with semaglutide is clear: higher doses produce greater weight loss, on average. Here is a simplified comparison based on the available clinical data:

• 0.25mg and 0.5mg: Primarily titration doses. Weight loss is modest and variable during these phases.
• 1.0mg: Meaningful appetite suppression and measurable weight loss. Cumulative weight loss of approximately 4 to 6 percent of body weight by week 12 in the STEP trials.
• 1.7mg and 2.4mg: Weight loss accelerates further. The 2.4mg maintenance dose produced the 14.9% average in the STEP 1 trial over 68 weeks.

This does not mean that 1mg is ineffective. For some patients, it is the right long-term dose. But for patients with more ambitious weight loss goals, the data supports continuing escalation toward higher doses.

Safety Considerations

As weight loss progresses, safety monitoring is important:

• Rapid or significant weight loss increases the risk of gallbladder problems. Report any sudden upper abdominal pain to your physician.
• Prioritize adequate protein intake to support muscle preservation during weight loss.
• Avoid extreme caloric restriction. Severe undereating can lead to nutrient deficiencies, fatigue, and metabolic adaptations that slow weight loss.
• Stay hydrated, especially if GI side effects are present.
• Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Frequently Asked Questions

Is the weight loss at 1mg permanent?

Weight loss maintained while on semaglutide requires continued treatment and lifestyle habits. Clinical data shows that weight tends to return when the medication is discontinued. Your physician can help you plan a long-term strategy for maintaining results.

How does the weight loss at 1mg compare to diet and exercise alone?

The STEP trials showed that semaglutide at the 2.4mg maintenance dose produced significantly more weight loss than lifestyle intervention alone (approximately 14.9% vs 2.4%). At 1mg, the advantage over lifestyle alone is present but smaller. The combination of medication plus lifestyle changes produces the best outcomes.

Will I lose more weight faster if I increase to a higher dose?

Generally, yes. The dose-response data supports greater weight loss at higher doses. However, the pace of weight loss is not purely about dose. Lifestyle factors, metabolic health, and individual biology all play roles. Your physician will guide the escalation timing.

What if I have not lost any weight at 1mg?

Some patients do not see significant scale changes during the titration phase. This does not necessarily mean the medication is failing. Factors like fluid retention, muscle gain from exercise, and changes in body composition can mask fat loss. If you are not seeing results after reaching a maintenance dose, your physician will evaluate the situation and consider adjustments.

Should I track my weight daily at 1mg?

Daily weighing can be useful for tracking trends but can also cause unnecessary anxiety from normal fluctuations. Most physicians recommend weighing one to two times per week at the same time of day. Focus on the overall trajectory over weeks and months rather than day-to-day changes.

Data-Driven Weight Management at FormBlends

At FormBlends, our physicians use clinical data and your personal metrics to set realistic weight loss expectations at every dose. We track your progress, adjust your plan when needed, and help you understand what the numbers mean for your specific situation.

Ready for a personalized weight loss plan? Schedule a consultation with a FormBlends physician today.